Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mRNA
Biotech
BioNTech, Genentech cancel ph. 2 test of personalized cancer vax
An independent safety board recommended the trial be terminated early after more deaths were observed in patients given the customized mRNA vaccine.
Darren Incorvaia
Aug 28, 2026 1:50pm
With mRNA back in the spotlight, tRNA shows potential
Aug 27, 2026 2:00pm
Merck-Moderna vaccine data spur talk of Keytruda-like impact
Aug 20, 2026 9:25am
After 5-month wait, BioNTech reveals Sobi CEO will take top job
Aug 3, 2026 7:35am
Moderna enters in vivo CAR-T with autoimmune asset
Jun 26, 2026 9:00am
Spurned by FDA, Passage Bio finds exit through Remix
Jun 24, 2026 5:20pm
